Portal de Periódicos da CAPES

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

2020; Elsevier BV; Volume: 135; Issue: 21 Linguagem: Inglês

10.1182/blood.2020006288

1528-0020

Steven P. Treon, Jorge J. Castillo, Alan P Skarbnik, Jacob D. Soumerai, Irene M. Ghobrial, Maria Luisa Guerrera, Kirsten Meid, Guang Yang,

PI3K/AKT/mTOR signaling in cancer

Treon et al provide early clinical data supporting a theoretical rationale for continuing ibrutinib in patients receiving the drug during COVID-19 illness.